Publications

Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response.
J Rheumatol 2016 08 1;43(8):1566-74. Epub 2016 Jun 1.
From the ACURA Centre for Rheumatic Diseases, Baden-Baden; Department of Internal Medicine V, University of Heidelberg, Heidelberg; Department of Pneumology, Klinikum Löwenstein, Löwenstein; Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum, Bochum, Germany.J. Bauhammer, MD, ACURA Centre for Rheumatic Diseases; N. Blank, MD, Department of Internal Medicine V, University of Heidelberg; R. Max, MD, Department of Internal Medicine V, University of Heidelberg; H.M. Lorenz, MD, ACURA Centre for Rheumatic Diseases, and Department of Internal Medicine V, University of Heidelberg; U. Wagner, MD, Department of Pneumology, Klinikum Löwenstein; D. Krause, MD, Department of Medical Informatics, Biometry and Epidemiology, Ruhr University Bochum; C. Fiehn, MD, ACURA Centre for Rheumatic Diseases.

Timing of onset affects arthritis presentation pattern in antisyntethase syndrome.
Clin Exp Rheumatol 2018 Jan-Feb;36(1):44-49. Epub 2017 Jul 26.
Division of Rheumatology, University and IRCCS Policlinico S. Matteo Foudation, Pavia, Italy.

OF